High expression of transient potential receptor C6 correlated with poor prognosis in patients with esophageal squamous cell carcinoma

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Zhang, Shui Shen ^a   Wen, Jing ^a   Yang, Fu ^a   Cai, Xiao Li ^b   Yang, Hong ^a   Luo, Kong Jia ^a   Liu, Qian Wen ^a   Hu, Rong Gui ^a   Xie, Xuan ^a   Huang, Qing Yuan ^a   Chen, Jun Ying ^a   Fu, Jian Hua ^a   Hu, Yi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Esophageal squamous cell carcinoma; Prognosis; Transient potential receptor C6; Up regulated

Indexed keywords

TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; MESSENGER RNA; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; DISEASE MARKER; DISEASE SPECIFIC SURVIVAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ESOPHAGUS TUMOR; FEMALE; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; TRPC CATION CHANNELS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84877763893     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0607-7     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Wei WQ YJ, Zhang SW, Chen WQ, Qiao YL. Analysis of the esophageal cancer mortality in 2004-2005 and its trends during last 30 years in China. Zhonghua Yu Fang Yi Xue Za Zhi. 2010;44: 398-402.
3. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
4. DE Clapham RL, Strubing C. The TRP ion channel family. Nat Rev Neurosci. 2001;2:387-96.
5. Lehen'kyi V, Prevarskaya N. Oncogenic TRP channels. Adv Exp Med Biol. 2011;704:929-45.
6. Shi Y, Ding X, He ZH, Zhou KC, Wang Q, Wang YZ. Critical role of TRPC6 channels in G2 phase transition and the development of human oesophageal cancer. Gut. 2009;58:1443-50.
7. Cai R, Ding X, Zhou K, Shi Y, Ge R, Ren G, Jin Y, Wang Y. Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells. Int J Cancer. 2009;125:2281-7.
8. Ding X, He Z, Zhou K, Cheng J, Yao H, Lu D, Cai R, Jin Y, Dong B, Xu Y, Wang Y. Essential role of TRPC6 channels in G2/M phase transition and development of human glioma. J Natl Cancer Inst. 2010;102:1052-68.
9. Wan Q, Zheng A, Liu X, Chen Y, Han L. Expression of transient receptor potential channel 6 in cervical cancer. Onco Targets Ther. 2012;5:171-6.
10. Dhennin-Duthille I, Gautier M, Faouzi M, et al. High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues correlation with pathological parameters. Cell Physiol Biochem. 2011;28:813-22.
11. El Boustany C, Bidaux G, Enfissi A, Delcourt P, Prevarskaya N, Capiod T. Capacitative calcium entry and transient receptor potential canonical 6 expression control human hepatoma cell proliferation. Hepatology. 2008;47:2068-77.
12. Yue D, Wang Y, Xiao JY, Wang P, Ren CS. Expression of TRPC6 in benign and malignant human prostate tissues. Asian J Androl. 2009;11:541-7.
13. Zlobec I, Steele R, Terracciano L, et al. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007;60:1112-6.
14. Zhu ZH, Sun BY, Ma Y, et al. Three immunomarker support vector machines-based prognostic classifiers for stage IB nonsmall-cell lung cancer. J Clin Oncol. 2009;27:1091-9.
15. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721-4.
16. Yu Y, Fantozz I, Remillard CV, et al. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci. 2004;101:13861-6.
17. Ge R, Tai Y, Sun Y, et al. Critical role of TRPC6 channels in VEGF-mediated angiogenesis. Cancer Lett. 2009;283:43-51.
18. Zadeh H, MA G, Magnussen CA, et al. VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 2008;15:605-14.
19. Guilbert A, Dhennin-Duthille I, Hiani YE, Haren N, Khorsi H, Sevestre H, Ahidouch A, Ouadid-Ahidouch H. Expression of TRPC6 channels in human epithelial breast cancer cells. BMC Cancer. 2008;8:125.
20. Thebault S, Flourakis M, Vanoverberghe K, et al. Differential role of transient receptor potential channels in Ca2 + entry and proliferation of prostate cancer epithelial cells. Cancer Res. 2006;66:2038-47.
21. Berridge MJ, Bootman MD, Roderick HL. Calcium: calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4:517-29.
22. Roderick HL, Cook SJ. Ca2 + signalling checkpoints in cancer: remodelling Ca2 + for cancer cell proliferation and survival. Nat Rev Cancer. 2008;8:361-75.
23. Ding X, He Z, Shi Y, et al. Targeting TRPC6 channels in oesophageal carcinoma growth. Expert Opin Ther Targets. 2010;14:513-27.
24. Peng JB, Zhuang L, Berger UV, et al. CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun. 2001;282:729-34.
25. Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H, et al. Expression of the Ca2 + selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene. 2003;22:7858-61.
26. Lee J, Lee KE, Im YH, Kang WK, Park K, Kim K, Shim YM. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2005;80:1170-5.
27. Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol. 2003;21:4592-6.
28. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-92.
29. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-34.
30. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681-92.
31. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659-68.
32. van Hagen P, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.
33. Geard CR, Schiff PB. Taxol and radiation. J Natl Cancer Inst Monogr. 1993;15:89-94.
34. Tishler RB, Geard CR, et al. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 1992;22:613-7.